STX 478
Alternative Names: LY-4064809; ST-814; STX-478; STX-H1047-PI3Ka inhibitors - Scorpion TherapeuticsLatest Information Update: 23 Sep 2025
At a glance
- Originator Scorpion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 20 May 2025 Eli Lilly and Company initiates enrolment in the phase I (In volunteers) trial in the US (NCT06991179)
- 06 May 2025 Eli Lilly and Company completes the phase I trial (In volunteers) in the US (NCT06901336)
- 25 Apr 2025 Pharmacodynamics data from preclinical trial in Colorectal cancer (CRC) presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)